It's a familiar story these days: Companies file for initial public offerings with high hopes but usually settle for less. (BioWorld Today)

It's a familiar story these days: Companies file for initial public offerings with high hopes but usually settle for less. (BioWorld Today)

A week after reporting that additional trials likely would be necessary for approval of its sleep drug, indiplon, Neurocrine Biosciences Inc. suffered another blow with the loss of its commercialization partner, Pfizer Inc. (BioWorld Today)